Published:
ISTO Technologies, Inc. to Present at 2nd Annual Jefferies & Company, Inc. Healthcare Conference
ST. LOUIS, June 4 /PRNewswire/ -- ISTO Technologies, Inc., a privately
held orthobiologic company, announced today that it will participate in the
2nd Annual Jefferies & Company, Inc. Healthcare Conference inNew York, NY
from June 24-26, 2008. Mitchell Seyedin, Ph. D., President and CEO of ISTO,
will present on Thursday, June 26th at 9:00 a.m. Eastern Time. The conference
will showcase a diverse group of companies and industry experts in the areas
of biotechnology, CROs, healthcare facilities & services, healthcare IT
services, medical devices & diagnostics, pharmaceutical services and specialty
pharmaceuticals.
ISTO, an orthobiologic company, is focused on developing breakthrough
products to regenerate and restore damaged cartilage and bone for sports
medicine and spinal therapy indications. Cartilage regeneration is often
called the "holy grail" of the orthopedic industry because of its potential to
restore function to damaged joints that otherwise have limited healing
potential. Cartilage serves as a "shock absorber" protecting all joints,
including spinal discs, from the wear and tear experienced during motion.
ISTO's innovative products are designed to address very large markets with
unmet clinical needs.
The Company's leading cartilage product is DeNovo(R) ET, a
laboratory-grown engineered cartilage tissue grown from juvenile chondrocytes
using ISTO's cell-based platform technology. DeNovo ET is a scaffold-free
living cartilage designed to repair and restore joint function in the knee.
The surgeries and primary endpoints of the Phase I/II human clinical trials
are nearing completion and the data collection process is currently underway.
ISTO's development pipeline also includes NuQu(TM), a cell-based
injectable formulation of juvenile chondrocytes for nucleus regeneration of
the spinal disc. Degeneration of disc cartilage begins in the nucleus and is
accompanied by cell death and tissue destruction. NuQu has been developed for
use in conjunction with a minimally invasive, non-surgical, outpatient
procedure.
ISTO's third major program is InQu(R), an osteobiologic bone graft
extender for spinal applications, which was launched as a commercial product
in March 2008. InQu is a differentiated biomaterial scaffold of synthetic and
biologic polymers. It is designed to facilitate the growth of host repair
responses in any tissue to which it is implanted. ISTO's hybrid scaffold
represents a new class of biomaterials that combine the best properties of
synthetic polymers and biological materials to create a product with superior
structure and biological activity over currently available scaffold implants.
InQu is a product with great biology, shape, form and controlled resorption
rate.
About ISTO
ISTO Technologies, Inc. is developing and marketing clinical solutions for
sports medicine, spinal therapy, and trauma. ISTO's products are intended for
the repair and regeneration of damaged or injured cartilage and bone. For
additional information on ISTO, please visit our website at
http://www.istotech.com or contact Scott Gill, Chief Financial Officer, at
314-995-6049.
SOURCE ISTO Technologies, Inc.
Copyright © 2009, PRNewswire
Copyright © 2009, NewsBlaze,
Daily NewsTags: ,HEA,MTC,CCA,TDS,MO-ISTO-Technologies
Search News
Daily News
